David A Wood, Catriona S Jennings, Kornelia Kotseva, Agnieszka Adamska, Iris Erlund, Sandra Ganly, Per-Henrik Groop, Susan Hennessy, Maarten J G Leening, Linda Mellbin, Kausik K Ray, Lars Ryden, Terhi Vihervaara, Victor Aboyans, Ana Abreu, Carlos Aguiar, Karl Andersen, Jolita Badariene, Jan Bruthans, Monika Burzynska, Almudena Castro Conde, Renata Cifkova, Furio Colivicchi, Kairat Davletov, Mirza Dilic, Elena Dimitrova, Maryna Dolzhenko, Vilnis Dzerve, Andrejs Erglis, Zlatko Fras, Baris Gungor, Peter Heuschmann, Piotr Jankowski, Iulia Kulcsar, Nebojsa M Lalic, Seppo Lehto, Dragan Lovic, Aldo P Maggioni, Fabrice Mac Martens, Lampros K Michalis, Davor Milicic, Erkin Mirrakhimov, Greg Murphy, Oner Ozdogan, Jurgita Plisiene, Zeljko Reiner, Stefan Stoerk, Lale Tokgozoglu, Jamol Uzokov, Dusko Vulic, Dirk De Bacquer, John W McEvoy, EUROASPIRE VI country Investigators
Most European patients are not achieving targets set by prevention guidelines. There is marked variability in CR attendance, evidence of inverse care with lowest attendance in highest risk regions, despite better outcomes for CR. These results inform the challenges for implementation of the first ESC guideline on CR.
BACKGROUND AND AIMS: This observational study investigated whether patients with coronary heart disease (CHD) in Europe are achieving the standards set by prevention and rehabilitation guidelines. Variability was studied: (i) between countries; (ii) between geographical risk regions; and (iii) attendance at cardiac rehabilitation (CR) with outcomes.
METHODS: Observational study between September 2024- February 2026 in 160 hospitals across 27 countries. Geographical risk regions were defined as high, moderate or low based on WHO cardiovascular mortality data.
RESULTS: Among 8590 patients with CHD (23.7% female), 17.1% were current smokers, 32.0% were obese and 33.5% reported low physical activity. 59.8% were above blood pressure target (systolic ≥ 130 and/or diastolic ≥ 80 mmHg), 82.7% were above LDL-C target (≥ 1.4 mmol/l), 32.8% had known diabetes of whom 42.2% had HbA1c ≥ 7% and 30.6% had chronic kidney disease. Prevalences of these risk factors were all highest in countries from high risk regions. 29.1% of patients attended at least one CR session, with country variability ranging from 0% to 79%, and differing by risk region (55.9% low risk, 29.7% moderate risk and 10.2% high risk; p < 0.001). Attendance at CR programme was associated with significantly better lifestyles, risk factor control and use of cardioprotective drugs.
CONCLUSIONS: Most European patients are not achieving targets set by prevention guidelines. There is marked variability in CR attendance, evidence of inverse care with lowest attendance in highest risk regions, despite better outcomes for CR. These results inform the challenges for implementation of the first ESC guideline on CR.